Grey Cloak Tech Inc (HYEX) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Grey Cloak Tech Inc $0.33, price $1.10, upside -69.9%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Grey Cloak Tech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.8209 – $16.56 · fair‑value band $0.1785 – $0.3485 · the $1.10 price screens above the $0.3315 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Grey Cloak Tech in your weekly email
Every Wednesday you see whether Grey Cloak Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Healthy Extracts Inc., through its subsidiaries, engages in acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals in the United States. It operates through Corporate and Health Supplements segments.
Show more
Healthy Extracts Inc., through its subsidiaries, engages in acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals in the United States. It operates through Corporate and Health Supplements segments. The company's proprietary and patented products target categories within the nutraceuticals market, such as heart, brain, and immune health. It also provides heart and immune health products, including bergamot-based products in tablet and capsule form; and plant-based health technology neuro-products that enhance brain health comprising memory, cognition, focus, and neuro-energy. The company was formerly known as Grey Cloak Tech Inc. and changed its name to Healthy Extracts Inc. in October 2020. Healthy Extracts Inc. was incorporated in 2014 and is headquartered in Henderson, Nevada.
Stock analysis
Grey Cloak Tech Inc (HYEX) currently trades at $1.10, while our model-based Fair Value estimate is $0.3315, implying the stock looks roughly 231.8% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $1.09 per share, and 0 of the 7 models we run sit above the $1.10 price.
Bear case: the Multiples group reads lowest at $0.1400, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.1785 (bear) to $0.3485 (bull), the price of $1.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Grey Cloak Tech Inc reported revenue of $4.5M in FY2025 versus $1.5M in FY2021, a compound +32.5%/yr. Reported net income was −$881K in FY2025.
Key figures
Market cap $39.8M · P/E ratio 90.0 · P/S ratio 7.66 · EPS (TTM) $0.0300 · Net margin −19.5% · Return on equity −5.7% · Return on assets (EBIT) −38.3% · Operating margin −20.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 59% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −70%, HYEX screens richer than that median.
Fair Value models
Bear $0.1785Fair Value $0.3315Bull $0.3485
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0223 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+44.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.7%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.1%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−160.8% (2020) → −20.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +43.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 621 stocks
Beats the industry median on 2/10 measures
Overall it trails its industry peers.
Valuation
Quality Score40 · Bottom 25%
Fair Value upside−69.9% · Bottom 25%
Profitability
Return on assets−4.9% · Bottom 25%
Net margin (TTM)−13.2% · Bottom 25%
Operating margin (TTM)−20.4% · Bottom 25%
Growth and dividend
Revenue growth73.0% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)90.0× · Priciest 25%
P/B1.66× · Cheaper than median
P/S (TTM)7.66× · Priciest 25%
P/FCF272.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 18
PAST (return on equity)0· sector 26
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Grey Cloak Tech Inc (HYEX) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.3315 versus a price of $1.10, about −70% upside (overvalued).
What is the fair value of HYEX?
Our model-based fair value for Grey Cloak Tech Inc is $0.3315 (as of Sep 27, 2026), built from audited fundamentals. The current price: $1.10.
What is the quality score of HYEX?
Grey Cloak Tech Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Grey Cloak Tech Inc (HYEX)?
Our model-based price target is the fair value of $0.3315 (as of Sep 27, 2026) from 7 valuation models. Cautious scenario $0.1785, optimistic scenario $0.3485. It is a calculation from audited fundamentals, not an analyst target.
What is the Grey Cloak Tech Inc stock forecast for 2026?
Our models put fair value at $0.3315, about −70% upside versus a price of $1.10 (overvalued). Cautious scenario $0.1785, optimistic scenario $0.3485. The calculation is refreshed regularly with new filings.
What is the revenue of Grey Cloak Tech Inc (HYEX)?
Grey Cloak Tech Inc reported trailing-twelve-month revenue of about $5.2M (latest available figure, as of Sep 27, 2026).
What growth is priced into Grey Cloak Tech Inc (HYEX)?
For today's price to be fair in a discounted-cash-flow model, Grey Cloak Tech Inc would have to grow free cash flow by +46.8 % per year for five years (discount rate 9.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +28.7 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of HYEX use?
Our models discount Grey Cloak Tech Inc at 9.7 %: a base by market capitalisation (nano), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Grey Cloak Tech Inc that is +46.8 % per year a year over ten years, using the same discount rate (9.7 %) and the same formula as our fair value.
How much growth has Grey Cloak Tech Inc (HYEX) delivered so far?
Over the past 5 years revenue at Grey Cloak Tech Inc grew +28.7 % a year. The price currently implies +46.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Grey Cloak Tech Inc (HYEX) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Grey Cloak Tech Inc (+46.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Grey Cloak Tech Inc (HYEX)?
The free-cash-flow yield on the price is 0.79 %: that much free cash flow Grey Cloak Tech Inc produces per unit of market value. When it exceeds the discount rate of our models (9.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Grey Cloak Tech Inc (HYEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Grey Cloak Tech Inc it is $0.3315 per share (as of Sep 27, 2026), against a price of $1.10. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Grey Cloak Tech Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, HYEX trades above its calculated fair value: price $1.10, fair value $0.3315, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HYEX?
No. The price is what the market pays today ($1.10); the fair value is what the company's own numbers justify ($0.3315). For Grey Cloak Tech Inc the two are $0.7685 per share apart. That gap is exactly why we show both numbers side by side.
How much is Grey Cloak Tech Inc worth?
The market values Grey Cloak Tech Inc at about $39.8M (market capitalisation, as of Sep 27, 2026). Per share that is $1.10; our models calculate a fair value of $0.3315 per share.
What do the bullish and bearish scenarios say about HYEX?
Our models span a range for Grey Cloak Tech Inc: cautious scenario $0.1785, base $0.3315, optimistic $0.3485 per share (as of Sep 27, 2026, price $1.10). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HYEX?
Grey Cloak Tech Inc trades at a price-to-earnings ratio of 90.0 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.3315 is built from several models across several years. Other multiples: P/B 1.7, P/S 7.7.
How solid is the balance sheet of Grey Cloak Tech Inc (HYEX)?
Balance-sheet figures for Grey Cloak Tech Inc (as of Sep 27, 2026): return on equity −5.7%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is HYEX from its 52-week high?
Grey Cloak Tech Inc trades at $1.10, about 59% below its 52-week high of $2.70 and 34% above the low of $0.8209 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3315 is for.
Which stocks are comparable to Grey Cloak Tech Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Grey Cloak Tech Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $1.10, calculated fair value $0.3315 (−70%), Quality Score 40/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HYEX calculated?
We run Grey Cloak Tech Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3315, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Grey Cloak Tech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Grey Cloak Tech Inc (HYEX)?
The closing price on Sep 25, 2026 was $1.10. Our model-based fair value is $0.3315, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Grey Cloak Tech Inc right now?
The price sits above even our optimistic bull case ($0.3485). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1785 to $0.3485) leaves room in how you read the outcome.
Key figures of Grey Cloak Tech Inc
How large is the market capitalisation of Grey Cloak Tech Inc (HYEX)?
The market capitalisation of Grey Cloak Tech Inc is $39.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Grey Cloak Tech Inc (HYEX)?
The price-to-sales ratio of Grey Cloak Tech Inc is 7.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Grey Cloak Tech Inc (HYEX)?
Earnings per share at Grey Cloak Tech Inc are $0.0300 (price ÷ EPS = P/E 90.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Grey Cloak Tech Inc (HYEX)?
The net margin of Grey Cloak Tech Inc is −19.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Grey Cloak Tech Inc (HYEX)?
The return on equity (ROE) of Grey Cloak Tech Inc is −5.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Grey Cloak Tech Inc (HYEX)?
On an EBIT basis the return on assets of Grey Cloak Tech Inc is −38.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Grey Cloak Tech Inc (HYEX)?
The operating margin of Grey Cloak Tech Inc is −20.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Grey Cloak Tech Inc (HYEX)?
Revenue at Grey Cloak Tech Inc is growing +73.0% versus a year earlier (3y avg +26.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Grey Cloak Tech Inc (HYEX)?
Earnings per share at Grey Cloak Tech Inc are growing −42.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Grey Cloak Tech Inc (HYEX) carry?
The net debt of Grey Cloak Tech Inc is $2.0M (fiscal year 2025, ≈ 13.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Grey Cloak Tech Inc in the live analysis
One click puts Grey Cloak Tech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026